Clarient has launched a new gene mutation test to help physicians select the appropriate therapy for non-small cell lung cancer.
While biotech leaders from all over the world gathered at the 2009 BIO International Convention in Atlanta, financing activity in the sector raised hope that the cloud hanging over the industry may be lifting a little.
Researchers found that Dendreon’s immunotherapy drug Provenge prolonged the lives of advanced prostate cancer patients by an average of 4.1 months compared to a placebo.
The mechanisms that drive disease have long confounded the medical industry. How much of a part does genetics play? How does the patient’s lifestyle influence his or her risk of developing cancer? What makes one patient respond favorably to a particular treatment, while another suffers severe side effects?
The OneMedPlace finance conference for emerging med tech companies, the OneMedForum, will be held January 13-14 in San Francisco. Click here to learn more. Our featured panelists and speakers will be recognized […]
Magnetic resonance imaging (MRI) of the breast continues to show double digit growth in 2008 and is one of the fastest growing procedures in radiology departments, this according to Arlington Medical Resources […]
Our in-house dynamo, Claudia Pinzon and the rest of the the talented team at OneMedTV, have been busy compiling a wealth of valuable video content captured at AdvaMed2008. Below, some of that […]